Success Metrics

Clinical Success Rate

69.2%

Based on 9 completed trials

Completion Rate

69%(9/13)

Active Trials

3(13%)

Results Posted

78%(7 trials)

Terminated

4(17%)

Phase Distribution

Ph phase_1

17%

Ph phase_2

48%

Ph phase_4

13%

Ph not_applicable

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution21 total trials

Phase 1Safety & dosage

4(19.0%)

Phase 2Efficacy & side effects

11(52.4%)

Phase 3Large-scale testing

2(9.5%)

Phase 4Post-market surveillance

3(14.3%)

N/ANon-phased studies

1(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(9)

Terminated(4)

Other(5)

Detailed Status

Completed9

unknown5

Terminated4

Not yet recruiting2

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

69.2%

Most Advanced

Phase 4

Trials by Phase

Phase 14 (19.0%)

Phase 211 (52.4%)

Phase 32 (9.5%)

Phase 43 (14.3%)

N/A1 (4.8%)

Trials by Status

unknown522%

terminated417%

not_yet_recruiting29%

completed939%

active_not_recruiting14%

recruiting29%

Recent Activity

3 active trials

Showing 5 of 23

active_not_recruitingphase_2

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889

recruitingphase_2

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more

NCT04633889Phase 2

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

Active Not Recruiting

NCT04566991Phase 2

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Recruiting

NCT07023666Phase 2

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Recruiting

NCT07162363Phase 2

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

Not Yet Recruiting

NCT05748587

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Completed

NCT00749515Phase 4

Pilot Study for Patients With Poor Response to Deferasirox

Completed

NCT02875262Phase 1

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial

Unknown

NCT00777140Phase 2

Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion

Completed

NCT03137966Phase 2

Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers

Not Yet Recruiting

NCT02041299Phase 4

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Terminated

NCT04292314Phase 2

Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia

Completed

NCT04361032Phase 3

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Unknown

NCT04333550Phase 1

Application of Desferal to Treat COVID-19

Unknown

NCT01662895Phase 2

High-Dose Deferoxamine in Intracerebral Hemorrhage

Terminated

NCT00115349Phase 2

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Terminated

NCT02367248Phase 1

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Unknown

NCT00600938Phase 2

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Completed

NCT00000623

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed

NCT00000595Phase 2

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Completed

NCT00658411Not Applicable

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 23